These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 24638135)
21. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546 [TBL] [Abstract][Full Text] [Related]
22. Treatment of Alzheimer's disease: the beginning of a new era. Schenk D Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091 [No Abstract] [Full Text] [Related]
23. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Schenk DB; Seubert P; Grundman M; Black R Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006 [TBL] [Abstract][Full Text] [Related]
26. Immunotherapies for Alzheimer's disease. Golde TE; Levey AI Science; 2023 Dec; 382(6676):1242-1244. PubMed ID: 38096276 [TBL] [Abstract][Full Text] [Related]
27. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Taguchi H; Planque S; Nishiyama Y; Szabo P; Weksler ME; Friedland RP; Paul S Autoimmun Rev; 2008 May; 7(5):391-7. PubMed ID: 18486927 [TBL] [Abstract][Full Text] [Related]
28. [Advances in anti-beta antibody treatment of Alzheimer's disease]. Zhang JH; Liang P Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):633-5. PubMed ID: 18070457 [No Abstract] [Full Text] [Related]
29. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease. Murakami K Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729 [TBL] [Abstract][Full Text] [Related]
30. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Nitsch RM; Hock C Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453 [TBL] [Abstract][Full Text] [Related]
32. [The role of beta-amyloid peptide in pathogenesis and immunotherapy of Alzheimer's diseases]. Yu SN; Liu LY; Liang P Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):113-4. PubMed ID: 15842811 [No Abstract] [Full Text] [Related]
33. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
34. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy. Sengupta U; Nilson AN; Kayed R EBioMedicine; 2016 Apr; 6():42-49. PubMed ID: 27211547 [TBL] [Abstract][Full Text] [Related]
35. Aβ immunotherapy for Alzheimer's disease: where are we? Güell-Bosch J; Montoliu-Gaya L; Esquerda-Canals G; Villegas S Neurodegener Dis Manag; 2016 Jun; 6(3):179-81. PubMed ID: 27230296 [No Abstract] [Full Text] [Related]